Jason Hackney
Appearances
- DateMay 7, 2023The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
Presenter
Speakers
Icahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 21, 2024OSM-OSMR signaling is associated with IBD disease severity and non-response to anti-TNFs, and OSMR expression is associated with inflammatory fibroblasts…
- DateMay 19, 2024BACKGROUND: HIBISCUS I/II assessed the efficacy of etrolizumab versus adalimumab with a 10-week induction regimen in patients with ulcerative colitis (UC)…
